BRAF and neoplasm: While immune checkpoint inhibitors have shown significant efficacy in microsatellite instability-high (MSI-H) tumours and combined EGFR/BRAF inhibitor therapy has proven effective in BRAF V600E-mutant CRC, these treatments are only applicable to specific patient subgroups (3–5).